Table 2.

The effects of GSTM1, GSTT1 and GSTP1 genotypes on the incidences of short-term adverse drug reactions (myelosuppression, GI toxicity and infection event) induced by pulsed high-dose cyclophosphamide (CTX) therapy in SLE patients stratified by gender, age, and total CTX dose

		Myelotoxicity		GI toxicity		Infection event
Factor	Genotype	OR	95% CI	OR	95% CI	OR	95% CI
Gender (n)
Male (14)	GSTM1(-) vs. (+)	1.88	0.20, 17.27	0.56	0.31, 1.00	0.67	0.42, 1.06
	GSTT1(-) vs. (+)	0.53	0.06, 4.91	0.50	0.04, 6.68	0.88	0.06, 12.98
	GSTP1(I/I) vs. (I/V or V/V)	3.33	0.36, 30.70	7.00	0.50, 97.75	3.50	0.24, 51.90
Female (88)	GSTM1(-) vs. (+)	1.43	0.60, 3.40	1.25	0.50, 3.08	2.19	0.62, 7.74
	GSTT1(-) vs. (+)	0.74	0.31, 1.76	1.17	0.47, 2.88	0.97	0.30, 3.15
	GSTP1(I/I) vs. (I/V or V/V)	5.00*	1.96, 12.76	2.33	0.93, 5.88	2.33	0.71, 7.68
Age (n)
<30 (years) (56)	GSTM1(-) vs. (+)	2.09	0.66, 6.65	1.31	0.42, 4.07	7.04	0.82, 60.82
	GSTT1(-) vs. (+)	0.73	0.24, 2.19	1.17	0.39, 3.55	2.27	0.51, 10.18
	GSTP1(I/I) vs. (I/V or V/V)	7.50*	2.14, 26.24	2.80	0.87, 9.04	1.89	0.44, 8.09
≥30 years (46)	GSTM1(-) vs. (+)	0.92	0.30, 2.82	1.92	0.52, 7.12	1.40	0.28, 7.12
	GSTT1(-) vs. (+)	0.61	0.19, 1.96	0.97	0.27, 3.52	0.28	0.05, 1.62
	GSTP1(I/I) vs. (I/V or V/V)	2.83	0.85, 9.46	2.80	0.74, 10.52	4.00	0.69, 23.30
Total dose (n)
≤1 g (55)	GSTM1(-) vs. (+)	1.39	0.45, 4.34	2.00	0.59, 6.76	3.17	0.34, 29.23
	GSTT1(-) vs. (+)	0.54	0.18, 1.61	1.23	0.40, 3.78	0.82	0.15, 4.44
	GSTP1(I/I) vs. (I/V or V/V)	1.80	0.58, 5.61	3.33*	1.03, 10.79	4.53	0.75, 27.50
>1 g (47)	GSTM1(-) vs. (+)	1.72	0.53, 5.57	1.09	0.30, 3.92	3.83	0.85, 17.30
	GSTT1(-) vs. (+)	0.90	0.28, 2.89	0.86	0.24, 3.09	1.06	0.26, 4.27
	GSTP1(I/I) vs. (I/V or V/V)	12.88*	3.16, 52.57	1.83	0.48, 6.95	1.64	0.40, 6.70

CI Confidence interval; G, gastrointestinal; OR = Odds ratio.

^*P < 0.05.